Aclaris Therapeutics (NASDAQ:ACRS) Announces Earnings Results, Misses Expectations By $0.01 EPS

Aclaris Therapeutics (NASDAQ:ACRS) announced its earnings results on Thursday. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01), reports. Aclaris Therapeutics had a negative net margin of 900.01% and a negative return on equity of 39.73%. The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $2.07 million.

Here are the key takeaways from Aclaris Therapeutics’ conference call:

• 2026 is a major catalyst year for Aclaris with multiple near‑term readouts and filings, including the bosakitug Phase II completion, ATI‑052 Phase I/1b readouts, further development of ATI‑2138, and an expected IND for ATI‑9494 by year‑end.
• bosakitug is positioned as a potential best‑in‑class anti‑TSLP (reported ~400‑hour retention and ~23‑day half‑life) after strong Phase 2a EASI‑75 signals, with a larger Phase II AD readout expected in H2 2026.
• ATI‑052 (TSLP/IL‑4R bispecific) showed a ~26‑day half‑life in healthy volunteers, up to six weeks of 100% PD inhibition at 360 mg, and ~4x greater potency than tezepelumab+dupilumab in PBMC assays; AD and asthma 1b studies read out in H2.
• ATI‑2138 (ITK/JAK3 dual inhibitor) has promising efficacy signals (including preclinical alopecia data) but retains JAK‑class safety and labeling risk the company acknowledges as a potential liability.
• Aclaris is advancing an ITK‑selective program (lead ATI‑9494, ITK/TXK) to reduce JAK cross‑reactivity, with IND‑enabling studies ongoing and an IND targeted by the end of the year.

Aclaris Therapeutics Price Performance

Shares of NASDAQ ACRS traded down $0.18 during trading on Thursday, reaching $3.13. 1,576,073 shares of the stock traded hands, compared to its average volume of 2,218,559. The company has a 50-day moving average of $3.25 and a 200-day moving average of $2.58. Aclaris Therapeutics has a 52-week low of $1.05 and a 52-week high of $4.89. The stock has a market capitalization of $339.14 million, a P/E ratio of -2.27 and a beta of 0.86.

Hedge Funds Weigh In On Aclaris Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Millennium Management LLC grew its holdings in Aclaris Therapeutics by 111.0% during the first quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock valued at $6,325,000 after purchasing an additional 2,175,101 shares during the period. Geode Capital Management LLC raised its holdings in Aclaris Therapeutics by 108.4% during the 2nd quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock valued at $3,501,000 after buying an additional 1,282,042 shares during the period. Kotler Kevin bought a new stake in Aclaris Therapeutics in the fourth quarter worth about $5,135,000. Palo Alto Investors LP grew its position in Aclaris Therapeutics by 12.7% in the 3rd quarter. Palo Alto Investors LP now owns 1,566,840 shares of the biotechnology company’s stock valued at $2,977,000 after acquiring an additional 176,812 shares during the last quarter. Finally, State Street Corp grew its stake in Aclaris Therapeutics by 35.3% in the fourth quarter. State Street Corp now owns 1,506,403 shares of the biotechnology company’s stock worth $4,534,000 after purchasing an additional 393,257 shares in the last quarter. Institutional investors own 98.34% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ACRS shares. Craig Hallum assumed coverage on shares of Aclaris Therapeutics in a report on Friday, January 30th. They issued a “buy” rating and a $10.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, December 29th. Finally, HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Aclaris Therapeutics in a research note on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Aclaris Therapeutics has an average rating of “Moderate Buy” and an average target price of $9.80.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.